S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Urgent Warning (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Urgent Warning (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Urgent Warning (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Buy THIS stock before Taiwan is attacked (Ad)
Germany, EU reach agreement in combustion engine row
Intel co-founder, philanthropist Gordon Moore dies at 94
Urgent Warning (Ad)
'What can we do?': Millions in African countries need power
Judge rules online archive's book service violated copyright
Urgent Warning (Ad)
Biden's moves on Alaska drilling, TikTok test young voters
Ruling halts oil exports from Iraq's Kurdish area via Turkey
NASDAQ:FBIO

Fortress Biotech - FBIO Stock Forecast, Price & News

$0.75
+0.01 (+1.34%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.73
▼
$0.79
50-Day Range
$0.66
▼
$1.10
52-Week Range
$0.48
▼
$1.53
Volume
212,030 shs
Average Volume
837,657 shs
Market Capitalization
$85.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Fortress Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
695.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Fortress Biotech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.85) to ($0.97) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

220th out of 1,005 stocks

Pharmaceutical Preparations Industry

92nd out of 486 stocks

See Top Rated MarketRank™ Stocks Here

FBIO stock logo

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

March 22, 2023 | finance.yahoo.com
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
March 7, 2023 | finance.yahoo.com
Fortress Biotech to Participate in Two March 2023 Investor Conferences
March 26, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 7, 2023 | finance.yahoo.com
Journey Medical Corporation to Participate in the 35th Annual ROTH Conference
March 2, 2023 | finance.yahoo.com
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
March 2, 2023 | finance.yahoo.com
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
February 19, 2023 | finance.yahoo.com
The Executive Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO), Lindsay Rosenwald, Just Bought 18% More Shares
February 16, 2023 | finance.yahoo.com
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
March 26, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
February 15, 2023 | finance.yahoo.com
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
February 10, 2023 | finance.yahoo.com
Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 28, 2023 | finance.yahoo.com
Insiders own 28% of Fortress Biotech, Inc. (NASDAQ:FBIO) shares but individual investors control 41% of the company
January 20, 2023 | finance.yahoo.com
Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer
January 17, 2023 | finance.yahoo.com
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
January 17, 2023 | finance.yahoo.com
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
December 20, 2022 | finance.yahoo.com
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
December 15, 2022 | finance.yahoo.com
Checkpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 14, 2022 | finance.yahoo.com
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
December 6, 2022 | finance.yahoo.com
Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
November 15, 2022 | finance.yahoo.com
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 15, 2022 | finance.yahoo.com
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
November 8, 2022 | finance.yahoo.com
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
October 27, 2022 | finance.yahoo.com
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
October 26, 2022 | finance.yahoo.com
Insider Buying: The Fortress Biotech, Inc. (NASDAQ:FBIO) Executive Chairman Just Bought US$70k Worth Of Shares
October 7, 2022 | seekingalpha.com
Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 declares $0.1953 dividend
October 6, 2022 | markets.businessinsider.com
EQS-News: Fortress Bios Portfolio Of Marketed Drugs Could Soon See Three Additions
October 6, 2022 | finance.yahoo.com
Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions
See More Headlines
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings
11/15/2021
Today
3/25/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FBIO
CUSIP
21976U10
CIK
1429260
Web
www.fortressbiotech.com
Phone
(781) 652-4500
Fax
781-652-4545
Employees
173
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+695.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-64,700,000.00
Net Margins
-117.49%
Pretax Margin
-289.25%
Return on Equity
-54.56%
Return on Assets
-24.45%

Debt

Debt-to-Equity Ratio
0.91
Current Ratio
2.43
Quick Ratio
2.28

Sales & Book Value

Annual Sales
$68.79 million
Price / Sales
1.24
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.27 per share
Price / Book
0.33

Miscellaneous

Outstanding Shares
113,440,000
Free Float
83,607,000
Market Cap
$85.58 million
Optionable
Optionable
Beta
1.97

Key Executives

  • Lindsay Allan Rosenwald
    Chairman, President & Chief Executive Officer
  • David Jin
    CFO & Head-Corporate Development
  • George C. Avgerinos
    Senior Vice President-Biologics Operations
  • Michael Sean Weiss
    Director & Executive Vice Chairman-Strategy
  • Brian Achenbach
    Vice President-Finance & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings or view top-rated stocks.

What is Fortress Biotech's stock price forecast for 2023?

4 Wall Street research analysts have issued twelve-month price objectives for Fortress Biotech's stock. Their FBIO share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 695.3% from the stock's current price.
View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts.

How have FBIO shares performed in 2023?

Fortress Biotech's stock was trading at $0.6550 at the beginning of the year. Since then, FBIO stock has increased by 15.2% and is now trading at $0.7544.
View the best growth stocks for 2023 here.

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our FBIO earnings forecast.

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to analyst estimates of $18.41 million. Fortress Biotech had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 54.56%.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

Who are Fortress Biotech's major shareholders?

Fortress Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.40%), Jefferies Financial Group Inc. (3.99%), Opaleye Management Inc. (1.90%), Perkins Capital Management Inc. (0.76%), CI Private Wealth LLC (0.74%) and Millennium Management LLC (0.24%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends.

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $0.75.

How much money does Fortress Biotech make?

Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $85.58 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Fortress Biotech have?

The company employs 173 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 3/26/2023 by MarketBeat.com Staff